



October 2, 2014

Veracyte Inc. to Host Investor Day on October 9, 2014

- Webcast to Begin at 12:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., Oct 2, 2014 /PRNewswire/ -- [Veracyte Inc.](http://www.veracyte.com) (Nasdaq: VCYT) today announced that the company will host a live webcast in conjunction with its Investor Day on Thursday, October 9, 2014 at 12:00 p.m. ET in New York, NY.

The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at <http://investor.veracyte.com>. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 14 days following the presentation.

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, provides a comprehensive approach for assessing thyroid nodules, centered on the proprietary Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis. Each year, of the more than 525,000 thyroid nodule FNAs performed in the U.S., approximately 115,000 patients undergo diagnostic thyroid surgery, with 70% to 80% of nodules proving benign and thus the surgery unnecessary. Veracyte commercially launched Afirma in January 2011. As of June 30, 2014, the company has received nearly 115,000 FNA samples for evaluation using Afirma and has performed over 20,000 Afirma GECs to resolve indeterminate cytopathology results. Backed by multiple, peer-reviewed, published studies and included in leading medical guidelines, Afirma is covered by Medicare and major commercial payers, which collectively represent more than 135 million covered lives. Afirma is marketed and sold through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi. Veracyte intends to expand its molecular cytology franchise to other clinical areas and in September 2014 acquired Allegro Diagnostics Corporation to accelerate its entry into pulmonology with a clinically validated lung cancer test. Veracyte is also in product development for its second product in pulmonology, targeting idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:

Tracy Morris
650-380-4413
Tracy.morris@veracyte.com

Investors:

Ami Bavishi
Burns McClellan, Inc.
212-213-0006, ext. 344
abavishi@burnsmc.com

SOURCE Veracyte

News Provided by Acquire Media